Renata Pasqualini, is the Chief, Division of Cancer Biology, Department of Radiation Oncology at Rutgers Cancer Institute and Rutgers New Jersey Medical School having previously served as Associate Director for Translational Research and Chief of the Division of Molecular Medicine at the University of New Mexico Comprehensive Cancer Center. She has published more than 200 joint peer-reviewed research manuscripts and have more than 100 patents filed worldwide. Dr. Pasqualini’s lab discovered Prohibitin-TP01 which specifically targets the vasculature that nourishes white fat, a critical contributing factor in poor prostate cancer outcome. Preclinical studies in mouse models showed that TP01 treatment reduced white fat and resulted in ~30% weight reduction. Her goal is to successfully translate Prohibitin-TP01 into the clinic as a new agent for obese men with advanced prostate cancer.